Adult: As immediate-release tab/soln: 4-8 mg 3-4 times daily. As extended-release susp: 6-16 mg 12 hrly. Dosage should be individualised based on response and severity of condition. Child: As immediate-release preparation: 2-5 yr As soln: 1-2 mg 3-4 times daily; 6-11 yr As tab/soln: 2-4 mg 3-4 times daily; ≥12 yr Same as adult dose. As extended-release susp: 2-3 yr 3-4 mg 12 hrly; 4-5 yr 3-8 mg 12 hrly; 6-11 yr 6-12 mg 12 hrly; ≥12 yr Same as adult dose. Elderly: Initiate at lower end of dosing range.
Should be taken with food.
Concomitant use w/ MAOIs. Childn <2 yr. Lactation.
This drug may cause drowsiness and impaired mental or physical ability, if affected, do not drive or operate machinery.
Symptoms: Fixed and dilated pupils, dry mouth, flushing, GI symptoms, hallucinations, convulsions. Management: Symptomatic and supportive treatment. Employ activated charcoal and gastric lavage after ingestion of potentially life-threatening amount. Treat severe antimuscarinic effects w/ physostigmine. Treat hypotension w/ vasopressors.
May increase the effect of other antihistamines, barbiturates, TCAs, and CNS depressants (e.g. hypnotics, sedatives, tranquilisers). Potentially Fatal: MAOIs (e.g. phenelzine, tranylcypromine, selegiline) may prolong and intensify the anticholinergic effects of carbinoxamine.
May increase the effect of alcohol.
Description: Carbinoxamine, an ethanolamine derivative, is a sedating antihistamine w/ antimuscarinic and significant sedative properties. It competes w/ histamine in binding to H1-receptors on effector cells in the resp tract, blood vessels, and GI tract. Duration: Approx 4 hr (immediate-release). Pharmacokinetics: Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: 1.5-5 hr. Metabolism: Extensively metabolised in the liver. Excretion: Via urine (as inactive metabolites). Elimination half-life: 10-20 hr.
R06AA08 - carbinoxamine ; Belongs to the class of aminoalkyl ethers used as systemic antihistamines.
Anon. Carbinoxamine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 15/11/2016.Buckingham R (ed). Carbinoxamine Maleate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/11/2016.Carbinoxamine Maleate Tablet and Syrup (Breckenridge Pharamaceutical, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 15/11/2016.Karbinal ER Suspension, Extended Release (FSC Laboratories, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 15/11/2016.McEvoy GK, Snow EK, Miller J et al (eds). Carbinoxamine Maleate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 15/11/2016.